Biotech Can-Fite unlocks $4M to fund drug R&D and clinical trials

robot
Abstract generation in progress

Can-Fite BioPharma Ltd. announced it has entered into a definitive agreement for the immediate exercise of warrants, expected to generate approximately $4.0 million in gross proceeds. These funds will be allocated towards research and development, clinical trials, and general corporate purposes. The company will also issue new unregistered warrants as part of the transaction.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.
  • Reward
  • Comment
  • Repost
  • Share
Comment
Add a comment
Add a comment
No comments
  • Pin